A study from the Institute for Molecular Systems Biology, ETH Zurich, Zurich, Switzerland shows that “MicroRNAs 103 and 107 regulate insulin sensitivity.”
On the foundation of this interesting finding, Dr L Boominathan, Director-cum-chief Scientist of GBMD, reports here that: AntagomiR-based treatment for T2D: MiRNA-1 decreases insulin sensitivity via down regulation of a regulator of insulin receptor, Caveolin-1 . This study suggests that MiRNA-1, by down regulating its target gene, it may up regulate the regulator of insulin receptor, caveolin-1. Together, this study suggests that pharmacological formulations encompassing “Anti-MiRNA-1” may be used in the treatment of NIDDM.
Idea Proposed/Formulated by: Dr L Boominathan Ph.D.
Terms & Conditions apply http://genomediscovery.org/registration/terms-and-conditions/
To cite: Boominathan, L., AntagomiR-based treatment for T2D: MiRNA-18a decreases insulin sensitivity via down regulation of a regulator of insulin receptor, Caveolin-1, Genome-2-Bio-Medicine Discovery center (GBMD), 19/08/2014, 10.51 am, http://genomediscovery.org
Courtesy: When you cite drop us a line at email@example.com
* Research cooperation